Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy

Keyphrases

• Tafamidis 100%
• Transthyretin Amyloid Cardiomyopathy 100%
• Hospitalization 50%
• Placebo 50%
• All-cause Mortality 50%
• Low Dose Rate 37%
• Confidence Interval 25%
• 6-minute Walk Test (6MWT) 25%
• Decline Rate 25%
• Transthyretin 25%
• Kansas City Cardiomyopathy Questionnaire 25%
• Functional Quality 12%
• Quality of Life 12%
• Health Status 12%
• Placebo-controlled 12%
• Phase II Trial 12%
• Myocardium 12%
• Functional Capacity 12%
• Adverse Events 12%
• Dissociation 12%
• Amyloid Fibrils 12%
• High-score 12%
• Change from Baseline 12%
• Hazard Ratio 12%
• Relative Risk Ratio 12%
• Transthyretin Amyloidosis 12%
• Amyloidogenesis 12%
• Finkelstein-Schoenfeld 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Amyloid Protein 100%
• Myocardial Disease 100%
• Transthyretin 100%
• Tafamidis 100%
• Placebo 62%
• All Cause Mortality 50%
• Adverse Event 12%
• Functional Status 12%
• Health Status 12%
• Tetramer 12%